Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Uroplasty to similar businesses based on the strength of its analyst recommendations, valuation, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and price targets for Uroplasty and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Uroplasty Competitors 111 728 1026 10 2.50

As a group, “Medical Devices & Implants” companies have a potential upside of 36.02%. Given Uroplasty’s rivals higher possible upside, analysts plainly believe Uroplasty has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Uroplasty and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Uroplasty N/A N/A -4.07
Uroplasty Competitors $1.67 billion $207.58 million 87.35

Uroplasty’s rivals have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Uroplasty and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Uroplasty Competitors -101.23% -92.70% -30.32%

Volatility and Risk

Uroplasty has a beta of -1.26, indicating that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s rivals have a beta of 0.47, indicating that their average share price is 53% less volatile than the S&P 500.

Insider & Institutional Ownership

54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Uroplasty rivals beat Uroplasty on 6 of the 8 factors compared.

About Uroplasty

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.